WallStreetZenWallStreetZen

NASDAQ: FULC
Fulcrum Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for FULC

Based on 7 analysts offering 12 month price targets for Fulcrum Therapeutics Inc

Min Forecast
$7.00-45.23%
Avg Forecast
$17.00+33.02%
Max Forecast
$25.00+95.62%

Should I buy or sell FULC stock?

Based on 7 analysts offering ratings for Fulcrum Therapeutics Inc.

Buy
Strong Buy
3 analysts 42.86%
Buy
2 analysts 28.57%
Hold
1 analysts 14.29%
Sell
1 analysts 14.29%
Strong Sell
0 analysts 0%
Although FULC's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates FULC as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their FULC stock forecasts and price targets.

FULC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-11
lockedlocked$00.00+00.00%2025-12-09
lockedlocked$00.00+00.00%2025-12-08
lockedlocked$00.00+00.00%2025-12-08
lockedlocked$00.00+00.00%2025-12-08
HC Wainwright & Co.
Top 7%
94
BuyMaintains$25.00+95.62%2025-12-08
HC Wainwright & Co.
Top 1%
100
BuyUpgrades$12.00-6.10%2025-07-29

1 of 1

Forecast return on equity

Is FULC forecast to generate an efficient return?

Company
-30.75%
Industry
248.3%
Market
228.5%
FULC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is FULC forecast to generate an efficient return on assets?

Company
-28.39%
Industry
88.66%
FULC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FULC earnings per share forecast

What is FULC's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$1.20
Avg 2 year Forecast
-$1.23
Avg 3 year Forecast
-$1.41

FULC revenue forecast

What is FULC's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

FULC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FULC$12.78$17.00+33.02%Buy
GYRE$7.19$17.00+136.44%Strong Buy
VALN$8.46$15.50+83.22%Strong Buy
DBVT$20.27$46.00+126.94%Strong Buy
CTMX$4.12$7.25+75.97%Strong Buy
View Top Biotech Stocks

Fulcrum Therapeutics Stock Forecast FAQ

Is Fulcrum Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: FULC) stock is to Buy FULC stock.

Out of 7 analysts, 3 (42.86%) are recommending FULC as a Strong Buy, 2 (28.57%) are recommending FULC as a Buy, 1 (14.29%) are recommending FULC as a Hold, 1 (14.29%) are recommending FULC as a Sell, and 0 (0%) are recommending FULC as a Strong Sell.

If you're new to stock investing, here's how to buy Fulcrum Therapeutics stock.

What is FULC's earnings growth forecast for 2025-2027?

(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 42.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.51%.

Fulcrum Therapeutics's earnings in 2025 is -$71,114,000.On average, 12 Wall Street analysts forecast FULC's earnings for 2025 to be -$64,860,948, with the lowest FULC earnings forecast at -$64,173,644, and the highest FULC earnings forecast at -$64,211,527. On average, 12 Wall Street analysts forecast FULC's earnings for 2026 to be -$66,349,205, with the lowest FULC earnings forecast at -$80,614,825, and the highest FULC earnings forecast at -$48,300,706.

In 2027, FULC is forecast to generate -$76,095,936 in earnings, with the lowest earnings forecast at -$96,525,646 and the highest earnings forecast at -$57,392,603.

What is FULC's revenue growth forecast for 2025-2027?

(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.72%.

Fulcrum Therapeutics's revenue in 2025 is $0.On average, 11 Wall Street analysts forecast FULC's revenue for 2025 to be $0, with the lowest FULC revenue forecast at $0, and the highest FULC revenue forecast at $0. On average, 11 Wall Street analysts forecast FULC's revenue for 2026 to be $0, with the lowest FULC revenue forecast at $0, and the highest FULC revenue forecast at $0.

In 2027, FULC is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is FULC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: FULC) forecast ROA is -28.39%, which is lower than the forecast US Biotechnology industry average of 88.66%.

What is FULC's Price Target?

According to 7 Wall Street analysts that have issued a 1 year FULC price target, the average FULC price target is $17.00, with the highest FULC stock price forecast at $25.00 and the lowest FULC stock price forecast at $7.00.

On average, Wall Street analysts predict that Fulcrum Therapeutics's share price could reach $17.00 by Dec 11, 2026. The average Fulcrum Therapeutics stock price prediction forecasts a potential upside of 33.02% from the current FULC share price of $12.78.

What is FULC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: FULC) Fulcrum Therapeutics's current Earnings Per Share (EPS) is -$1.14. On average, analysts forecast that FULC's EPS will be -$1.20 for 2025, with the lowest EPS forecast at -$1.19, and the highest EPS forecast at -$1.19. On average, analysts forecast that FULC's EPS will be -$1.23 for 2026, with the lowest EPS forecast at -$1.49, and the highest EPS forecast at -$0.89. In 2027, FULC's EPS is forecast to hit -$1.41 (min: -$1.78, max: -$1.06).

What is FULC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: FULC) forecast ROE is -30.75%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.